UPDATE 1-Epix says no immediate FDA approval for imaging agent

(Reuters) - Epix shares rose nearly 20 percent to $6.99 in late
electronic trade after closing at $5.84 on the Nasdaq.




Blood pool agents help clinicians to light up a patient's
arteries to facilitate magnetic resonance imaging.


Read more at Reuters.com Government Filings News